Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today
announced the appointment of five leading experts in the fields of
neurological surgery and neuro-oncology to its Clinical Advisory
Board (CAB). The CAB will advise the Company as it advances its
nanoscale radiotherapeutics to treat rare brain and neurological
cancers.
“To successfully bring our investigational RNL
drug through the clinical development process, we will need
distinguished scientists and physicians standing with us, that have
unique perspectives and an intimate understanding of the key
clinical issues,” said Marc H. Hedrick, M.D., President and Chief
Executive Officer of Plus Therapeutics. “These doctors are leaders
in their fields and will be important to our efforts on behalf of
the patients with glioblastoma.”
New members of Plus’ CAB include:
Manish
Aghi,
M.D.,
Ph.D.,
Professor, Neurological Surgery, at the Weill Institute for
Neurosciences at the University of California, San Francisco.
Dr. Manish Aghi is a neurosurgeon, scientist and
current faculty member in the department of neurological surgery
and graduate division of biomedical sciences, as well as a
principal investigator in the Brain Tumor Research Center at UCSF.
He completed his MD-PhD Program through the Medical Scientist
Training Program at Harvard Medical School, followed by
neurological surgery residency and postdoctoral training at
Massachusetts General Hospital. Dr. Aghi serves as principal
investigator on multiple industry sponsored and
investigator-initiated Phase 1-2 clinical trials comparing
immunotherapy versus anti-angiogenic therapy of recurrent
glioblastoma, as well as investigating convection-enhanced delivery
of oncolytic viruses and nanoliposomal chemotherapy to recurrent
glioblastoma.
Nicholas
Butowski,
M.D.,
Professor, Neurological Surgery and Director, Translational
Research, Neuro-Oncology at the Weill Institute for Neurosciences
at the University of California, San Francisco.
Dr. Butowski is a neuro-oncologist who
specializes in brain tumors, neuroimaging, cognitive and
rehabilitative neurology, and complementary therapies for
neurological disorders. He is director of clinical services in
neuro-oncology and a co-investigator of National Cancer
Institute-supported North American Brain Tumor Consortium clinical
trials. Dr. Butowski earned his medical degree at the University of
Illinois at Chicago and completed a residency in neurology and a
fellowship in neuro-oncology at UCSF. He is a member of the
American Academy of Neurology, American Society of Clinical
Oncology and Society for Neuro-oncology.
Russell
Lonser,
M.D.,
Professor and Chair, Department of Neurological Surgery at The Ohio
State University Wexner Medical Center.
Dr. Lonser is a professor and chair of the
Department of Neurological Surgery at The Ohio State University
Wexner Medical Center, and currently holds the Dardinger Family
Chair in Neurosurgical Oncology. Previously, he was chief of the
Surgical Neurology Branch at the National Institutes of Health. Dr.
Lonser specializes in the resection of brain, spinal cord,
pituitary and brainstem tumors. He is a director on the American
Board of Neurological Surgeons, and was the head of the research
subcommittee in Head, Neck and Spine Injury Committee for the
National Football League. Dr. Lonser has served on the editorial
boards of NEUROSURGERY, World Neurosurgery, Journal of
Neurosurgery, PLoS One and Science Reports.
Alireza
Mohammadi,
M.D.,
Neurosurgeon at Cleveland Clinic Lerner College of Medicine of Case
Western Reserve University.
Dr. Mohammadi is a board-certified neurosurgeon
who specializes in neurosurgical oncology including surgery and
laser ablation of brain tumors as well as radiosurgery for brain
and spine. He is currently practicing at Neurosurgery Department
and the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
at the Cleveland Clinic. Since 2014, Dr. Mohammadi has also served
as an assistant professor in Neurological Surgery at the Cleveland
Clinic Lerner College of Medicine. Dr. Mohammadi earned his medical
degree from Tehran University School of Medicine in Tehran, Iran.
After completing his residency in neurosurgery at Shohada Hospital,
he went on to complete his fellowship in neuro-oncology surgery and
his fellowships in radiosurgery at the Cleveland Clinic.
Michael
Vogelbaum,
M.D.,
Ph.D.,
Chief of Neurosurgery and Program Leader of the Department of
Neuro-Oncology at Moffitt Cancer Center.
Dr. Vogelbaum is an internationally known leader
in neurosurgical oncology and distinguished investigator in
laboratory research, translational and clinical trials in gliomas.
He is currently Chief of Neurosurgery and Program Leader of the
Department of Neuro-Oncology at Moffitt Cancer
Center. Dr. Vogelbaum is also the inventor of patented
medical devices for delivering therapeutics directly to the brain
and brain tumors, with the first of these devices having received
U.S. Food and Drug Administration clearance. After completing his
M.D. and Ph.D. (Biomedical Engineering) at the University of
Virginia, Dr. Vogelbaum completed his residency in neurological
surgery at Barnes-Jewish Hospital in St. Louis, Mo.
About Plus Therapeutics,
Inc.
Plus Therapeutics (Nasdaq: PSTV) is a
clinical-stage pharmaceutical company whose radiotherapeutic
portfolio is concentrated on nanoliposome-encapsulated
radionuclides for several cancer targets. Central to the Company’s
drug development is a unique nanotechnology platform designed to
reformulate, deliver and commercialize multiple drugs targeting
rare cancers and other diseases. The platform is designed to
facilitate new delivery approaches and/or formulations of safe and
effective, injectable drugs, potentially enhancing the safety,
efficacy and convenience for patients and healthcare providers.
More information may be found at plustherapeutics.com and
respect-trials.com.
Cautionary Statement Regarding
Forward-Looking Statements
This press release contains certain statements
that may be deemed “forward-looking statements” within the meaning
of U.S. securities laws. All statements, other than statements of
historical fact, that address activities, events or developments
that we intend, expect, project, believe or anticipate and similar
expressions or future conditional verbs such as will, should,
would, could or may occur in the future are forward-looking
statements. Such statements are based upon certain assumptions and
assessments made by our management in light of their experience and
their perception of historical trends, current conditions, expected
future developments and other factors they believe to be
appropriate. These statements include, without limitation,
statements about: the Company’s potential to facilitate new
delivery approaches and/or formulations of safe and effective,
injectable drugs, potentially enhancing the safety, efficacy and
convenience for patients and healthcare providers; the Company’s
potential to develop drug candidates currently in its product
pipeline; and the Company’s potential to develop additional drugs
outside of its current pipeline. The forward-looking statements
included in this press release are subject to a number of
additional material risks and uncertainties, including but not
limited to: the risk that the Company is not able to successfully
develop product candidates that can leverage the U.S. FDA’s
accelerated regulatory pathways; and the risks described under the
heading “Risk Factors” in the Company’s Securities and Exchange
Commission filings, including in the Company’s annual and quarterly
reports. There may be events in the future that the Company is
unable to predict, or over which it has no control, and its
business, financial condition, results of operations and prospects
may change in the future. The Company assumes no responsibility to
update or revise any forward-looking statements to reflect events,
trends or circumstances after the date they are made unless the
Company has an obligation under U.S. federal securities laws to do
so.
Investor ContactPeter VozzoWestwicke/ICR(443)
377-4767Peter.Vozzo@westwicke.com
Media ContactTerri ClevengerWestwicke/ICR(203)
856-4326Terri.Clevenger@westwicke.com
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
From Apr 2023 to Apr 2024